• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    716.68 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    42 43 Next >
    Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
    Via Benzinga
    REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
    REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
    Via Benzinga
    3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
    It pays to develop novel medicines for life-threatening illnesses. 
    Via The Motley Fool
    Regeneron Earnings Miss; Biotech Giant's Stock Falls
    The biotech giant's earnings and sales both missed Q1 estimates. 
    Via Investor's Business Daily
    Regeneron Reports First Quarter 2024 Financial and Operating Results
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
    Via Benzinga
    Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
    Via Benzinga
    If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
    Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and... 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
    AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent. 
    Via Benzinga
    Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
    Via Benzinga
    Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
    Via Benzinga
    Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    2 Small-Cap Growth Stocks With Room To Run
    These two small-cap growth stocks could be ready to run. 
    Via The Motley Fool
    Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
    From Kirby McInerney LLP
    Via GlobeNewswire
    REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
    Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
    Via Benzinga
    The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    From Law Offices of Frank R. Cruz
    Via Business Wire
    Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
    The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
    Via Investor's Business Daily
    Topics Economy
    Exposures Interest Rates
    Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
    The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated... 
    Via Benzinga
    Topics Fraud
    Exposures Legal
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
    From Schall Law
    Via GlobeNewswire
    Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
    Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise. 
    Via Investor's Business Daily
    Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
    Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Should You Sell This Stock Following a Regulatory Roadblock?
    It's not the first such obstacle this high-performing drugmaker has faced. 
    Via The Motley Fool
    5 Healthcare Stocks to Buy for 2024
    Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    42 43 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.